Corcept Therapeutics enters the week after a strong earnings beat with shorts beating a steady retreat — and a high-profile analyst upgrade arriving just as the stock consolidates those gains.
The setup is a study in diverging signals. Short sellers have been unwinding positions aggressively since late April, yet insiders have been selling into the same rally. Options traders, meanwhile, are the most bullish they have been all year. The tension between those three reads is the story this week.
Short interest has fallen sharply over the past month. At 12.1% of the free float, it is down from a peak near 14.2% in mid-April. The move lower accelerated after the April 30 earnings print — when the stock jumped over 10% on the day — and continued through this week, with the SI % FF dropping roughly half a percentage point in five sessions. That is a meaningful unwind. Cost to borrow remains negligible at 0.49% APR, and borrow availability is wide, meaning there is no technical squeeze pressure driving the exit. Shorts appear to be leaving on fundamental grounds, not because they are being forced out. The ORTEX short score holds at 58.3, a mid-range reading that reflects an elevated but no longer extreme short position.
Options positioning reinforces the bullish tone. The put/call ratio has dropped to 0.63, near its 52-week low of 0.62 and well below its 20-day average of 0.75. That is the most call-heavy configuration seen in more than a year — a sharp reversal from April, when the PCR ran above 1.4 for nearly three consecutive weeks. The shift coincides precisely with the earnings catalyst and the subsequent ALS survival signal that Corcept disclosed alongside Q1 results. Investors who had been hedging aggressively through April have, broadly speaking, taken those hedges off.
The Street moved decisively this week. UBS upgraded CORT to Buy from Neutral this morning, lifting its target from $44 to $72 — one of the most aggressive single-session target revisions in recent months for the name. That follows Piper Sandler raising its Overweight target to $88 from $73 on May 1, and HC Wainwright lifting to $75 from $60 a few days earlier. The consensus among five analysts is a Buy, with a mean target of $79 — implying roughly 54% upside to Tuesday's close of $51.16. Bulls point to Korlym's commercial momentum, the FDA-approved Lifyorli in ovarian cancer, and the ALS cortisol data as potential pipeline optionality. Bears flag the ongoing Teva antitrust litigation — a court ruled this week that most claims must proceed — and the risk that generic competition eventually pressures Korlym pricing. The EPS momentum factor score ranks at the 93rd percentile on a 30-day basis, and the earnings surprise score sits at the 91st percentile, reflecting the consistent beat cadence that has rebuilt analyst confidence since the February trough. The PE multiple of 57x and EV/EBITDA near 43x leave limited room for execution misses.
Insider activity adds a note of caution to the bullish narrative. CEO Joseph Belanoff sold 40,000 shares for roughly $2 million on May 1, days after the earnings pop. Chief Level Officer William Guyer sold a further 20,000 shares on May 5 for just over $1 million. Both sales came at prices near $50-52 — the same range the stock trades today. The 90-day net insider position is modestly positive at roughly 321,000 shares, largely because Director George Baker bought around 100,000 shares in March at approximately $33. That buyer is now sitting on a significant unrealised gain. The executive selling, however, is a consistent pattern: Belanoff and Guyer have appeared on both sides of the ledger across multiple months, and both latest sales carry low significance scores, suggesting they are likely pre-planned programme trades rather than conviction-driven exits.
With no confirmed next earnings date in the calendar, the near-term watch points are the Teva antitrust proceedings, any updated Lifyorli label guidance or safety data, and whether the short unwind continues as the stock consolidates above $50.
See the live data behind this article on ORTEX.
Open CORT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
